← United States · Coverage record
US · SEC FORM 4
AtriCure, Inc.
ATRC · Nasdaq · CIK 0001323885 · Healthcare · Medical Instruments & Supplies
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
28 Form 4 transaction lines observed in the same window
12 sales · 16 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 8 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-05-30 · Privitera Salvatore.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- +5.4%
- 3M
- +60.4%
- 6M
- +97.7%
- 12M
- +59.1%
Volatility & liquidity
- Volatility
- 47.9%
- Beta
- —
- Avg daily value
- USD 61.2M
Valuation
- Market cap
- USD 2.8B
- P/E
- —
Fundamentals
- Profit margin
- -2.1%
- ROE
- -2.3%
- Industry
- Medical Instruments & Supplies
Market data
Price data up to: 2026-10-09 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-22 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 4,818,782
- Previous report
- 4,279,518
- Avg daily volume
- 1,848,072
- Days to cover
- 2.6
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-05-30 | Privitera Salvatore | Purchase (P) | Common Stock | 5,000 | USD 22.25 | USD 111,250 | SEC filing ↗ |
| 2021-04-30 | GROVES REGINA E | Purchase (P) | Common Stock | 34 | USD 76.68 | USD 2,607 | SEC filing ↗ |
| 2020-11-17 | Drake Scott William | Purchase (P) | Common Stock | 12,350 | USD 40.54 | USD 500,669 | SEC filing ↗ |
Form 4 evidence
62 transaction lines in the latest 365-day window; 457 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Privitera Salvatore | Sale (S) | Common Stock | 4,519 | USD 60.00 | USD 271,140 | SEC filing ↗ |
| 2026-09-11 | GROVES REGINA E | Sale (S) | Common Stock | 5,313 | USD 54.22 | USD 288,071 | SEC filing ↗ |
| 2026-09-08 | Privitera Salvatore | Sale (S) | Common Stock | 3,657 | USD 55.00 | USD 201,135 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Privitera Salvatore | Sale (S) | Common Stock | 4,519 | USD 60.00 | USD 271,140 | SEC filing ↗ |
| 2026-09-11 | GROVES REGINA E | Sale (S) | Common Stock | 5,313 | USD 54.22 | USD 288,071 | SEC filing ↗ |
| 2026-09-08 | Privitera Salvatore | Sale (S) | Common Stock | 3,657 | USD 55.00 | USD 201,135 | SEC filing ↗ |
| 2026-09-02 | Privitera Salvatore | Sale (S) | Common Stock | 7,763 | USD 52.50 | USD 407,558 | SEC filing ↗ |
| 2026-08-24 | Dahlquist Karl S. | Sale (S) | Common Stock | 9,370 | USD 48.89 | USD 458,099 | SEC filing ↗ |
| 2026-08-05 | Yuen Maggie | Sale (S) | Common Stock | 3,500 | USD 38.42 | USD 134,470 | SEC filing ↗ |
| 2026-08-05 | Prange Karen | Sale (S) | Common Stock | 3,564 | USD 38.80 | USD 138,283 | SEC filing ↗ |
| 2026-07-30 | CARREL MICHAEL H | Gift (G) | Common Stock | 4,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-29 | Noznesky Justin J | Sale (S) | Common Stock | 6,182 | USD 38.80 | USD 239,862 | SEC filing ↗ |
| 2026-07-28 | WEHRWEIN SVEN | Sale (S) | Common Stock | 25,000 | USD 37.84 | USD 946,000 | SEC filing ↗ |
| 2026-07-28 | WEHRWEIN SVEN | Option exercise / conversion (M) | Common Stock | 25,000 | USD 19.95 | USD 498,750 | SEC filing ↗ |
| 2026-07-28 | Doraiswamy Vinayak | Sale (S) | Common Stock | 6,000 | USD 38.88 | USD 233,280 | SEC filing ↗ |
| 2026-06-30 | Seith Douglas J | Award / grant (A) | Common Stock | 527 | USD 23.78 | USD 12,532 | SEC filing ↗ |
| 2026-06-30 | Privitera Salvatore | Award / grant (A) | Common Stock | 636 | USD 23.78 | USD 15,124 | SEC filing ↗ |
| 2026-06-30 | Doraiswamy Vinayak | Award / grant (A) | Common Stock | 636 | USD 23.78 | USD 15,124 | SEC filing ↗ |
| 2026-06-30 | Dahlquist Karl S. | Award / grant (A) | Common Stock | 636 | USD 23.78 | USD 15,124 | SEC filing ↗ |
| 2026-06-30 | CARREL MICHAEL H | Award / grant (A) | Common Stock | 636 | USD 23.78 | USD 15,124 | SEC filing ↗ |
| 2026-05-20 | Prange Karen | Sale (S) | Common Stock | 3,000 | USD 28.65 | USD 85,950 | SEC filing ↗ |
| 2026-05-18 | Yuen Maggie | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | WHITE ROBERT S. | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | WEHRWEIN SVEN | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | Telman Deborah H | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | Prange Karen | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | Nachman Shlomo | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | JOHNSON B KRISTINE | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-18 | GROVES REGINA E | Award / grant (A) | Common Stock | 6,144 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-15 | Doraiswamy Vinayak | Sale (S) | Common Stock | 5,000 | USD 28.13 | USD 140,650 | SEC filing ↗ |
| 2026-03-12 | Doraiswamy Vinayak | Sale (S) | Common Stock | 5,000 | USD 29.83 | USD 149,150 | SEC filing ↗ |
| 2026-03-10 | WHITE ROBERT S. | Option exercise / conversion (M) | Common Stock | 10,000 | USD 14.99 | USD 149,900 | SEC filing ↗ |
| 2026-03-06 | CARREL MICHAEL H | Gift (G) | Common Stock | 6,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ATRC |
| CIK | 0001323885 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 457 transaction lines from 2020-01-02 to 2026-09-23 3 P purchase lines · 123 S sale lines · 331 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.